Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Identifieur interne : 001511 ( PubMed/Corpus ); précédent : 001510; suivant : 001512Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Auteurs : Allan Lipton ; Matthew R. Smith ; Karim Fizazi ; Alison T. Stopeck ; David Henry ; Janet E. Brown ; Neal D. Shore ; Fred Saad ; Andrew Spencer ; Li Zhu ; Douglas J. WarnerSource :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2016.
Abstract
Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes in BTMs with overall survival (OS), disease progression (DP), and disease progression in bone (DPB) in patients with advanced cancer and bone metastases following denosumab or zoledronic acid treatment.
DOI: 10.1158/1078-0432.CCR-15-3086
PubMed: 27140926
Links to Exploration step
pubmed:27140926Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.</title><author><name sortKey="Lipton, Allan" sort="Lipton, Allan" uniqKey="Lipton A" first="Allan" last="Lipton">Allan Lipton</name><affiliation><nlm:affiliation>Division of Hematology/Oncology, Penn State Cancer Institute, Hershey, Pennsylvania. alipton@hmc.psu.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation><nlm:affiliation>Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation><nlm:affiliation>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Stopeck, Alison T" sort="Stopeck, Alison T" uniqKey="Stopeck A" first="Alison T" last="Stopeck">Alison T. Stopeck</name><affiliation><nlm:affiliation>Department of Internal Medicine, Stony Brook Cancer Center, Stony Brook, New York, New York.</nlm:affiliation></affiliation></author><author><name sortKey="Henry, David" sort="Henry, David" uniqKey="Henry D" first="David" last="Henry">David Henry</name><affiliation><nlm:affiliation>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania.</nlm:affiliation></affiliation></author><author><name sortKey="Brown, Janet E" sort="Brown, Janet E" uniqKey="Brown J" first="Janet E" last="Brown">Janet E. Brown</name><affiliation><nlm:affiliation>Academic Unit of Clinical Oncology, Experimental Cancer Medicine Center, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><affiliation><nlm:affiliation>Carolina Urologic Research Center, Myrtle Beach, South Carolina.</nlm:affiliation></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation><nlm:affiliation>Department of Surgery, University of Montreal Hospital Centers, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation><nlm:affiliation>Department of Clinical Haematology, Monash University, Melbourne, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name><affiliation><nlm:affiliation>Global Biostatistical Sciences, Amgen Inc., Thousand Oaks, California.</nlm:affiliation></affiliation></author><author><name sortKey="Warner, Douglas J" sort="Warner, Douglas J" uniqKey="Warner D" first="Douglas J" last="Warner">Douglas J. Warner</name><affiliation><nlm:affiliation>Clinical Development, Amgen Inc., Thousand Oaks, California.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27140926</idno><idno type="pmid">27140926</idno><idno type="doi">10.1158/1078-0432.CCR-15-3086</idno><idno type="wicri:Area/PubMed/Corpus">001511</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001511</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.</title><author><name sortKey="Lipton, Allan" sort="Lipton, Allan" uniqKey="Lipton A" first="Allan" last="Lipton">Allan Lipton</name><affiliation><nlm:affiliation>Division of Hematology/Oncology, Penn State Cancer Institute, Hershey, Pennsylvania. alipton@hmc.psu.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation><nlm:affiliation>Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation><nlm:affiliation>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Stopeck, Alison T" sort="Stopeck, Alison T" uniqKey="Stopeck A" first="Alison T" last="Stopeck">Alison T. Stopeck</name><affiliation><nlm:affiliation>Department of Internal Medicine, Stony Brook Cancer Center, Stony Brook, New York, New York.</nlm:affiliation></affiliation></author><author><name sortKey="Henry, David" sort="Henry, David" uniqKey="Henry D" first="David" last="Henry">David Henry</name><affiliation><nlm:affiliation>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania.</nlm:affiliation></affiliation></author><author><name sortKey="Brown, Janet E" sort="Brown, Janet E" uniqKey="Brown J" first="Janet E" last="Brown">Janet E. Brown</name><affiliation><nlm:affiliation>Academic Unit of Clinical Oncology, Experimental Cancer Medicine Center, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><affiliation><nlm:affiliation>Carolina Urologic Research Center, Myrtle Beach, South Carolina.</nlm:affiliation></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation><nlm:affiliation>Department of Surgery, University of Montreal Hospital Centers, Montreal, Quebec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation><nlm:affiliation>Department of Clinical Haematology, Monash University, Melbourne, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name><affiliation><nlm:affiliation>Global Biostatistical Sciences, Amgen Inc., Thousand Oaks, California.</nlm:affiliation></affiliation></author><author><name sortKey="Warner, Douglas J" sort="Warner, Douglas J" uniqKey="Warner D" first="Douglas J" last="Warner">Douglas J. Warner</name><affiliation><nlm:affiliation>Clinical Development, Amgen Inc., Thousand Oaks, California.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title><idno type="ISSN">1078-0432</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes in BTMs with overall survival (OS), disease progression (DP), and disease progression in bone (DPB) in patients with advanced cancer and bone metastases following denosumab or zoledronic acid treatment.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27140926</PMID><DateCreated><Year>2016</Year><Month>05</Month><Day>03</Day></DateCreated><DateRevised><Year>2016</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>23</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation></Journal><ArticleTitle>Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.</ArticleTitle><Pagination><MedlinePgn>5713-5721</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes in BTMs with overall survival (OS), disease progression (DP), and disease progression in bone (DPB) in patients with advanced cancer and bone metastases following denosumab or zoledronic acid treatment.</AbstractText><AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">This is an integrated analysis of patient-level data from three identically designed, blinded, phase III trials with patients randomized to subcutaneous denosumab or intravenous zoledronic acid. Levels of the BTMs urinary N-telopeptide (uNTx) and serum bone-specific alkaline phosphatase (sBSAP) measured at study entry and month 3 were analyzed. OS, DP, and DPB were compared in patients with BTMs ≥ median versus < median based on month 3 assessments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">uNTx levels ≥ the median of 10.0 nmol/mmol at month 3 were associated with significantly reduced OS compared with levels < median (HR for death, 1.85; P < 0.0001). sBSAP levels ≥ median of 12.6 ng/mL were associated with significantly reduced OS compared with levels < median (HR, 2.44; P < 0.0001). uNTx and sBSAP levels ≥ median at month 3 were associated with significantly greater risk of DP (HR, 1.31; P < 0.0001 and HR, 1.71; P < 0.0001, respectively) and DPB (HR, 1.11; P = 0.0407 and HR, 1.27; P < 0.0001, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BTM levels ≥ median after 3 months of bone antiresorptive treatment were associated with reduced OS and increased risk of DP and DPB. Assessment of uNTx and sBSAP levels after bone antiresorptive therapy may add to identification of patients at risk for worse clinical outcomes. Clin Cancer Res; 22(23); 5713-21. ©2016 AACR.</AbstractText><CopyrightInformation>©2016 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Allan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Penn State Cancer Institute, Hershey, Pennsylvania. alipton@hmc.psu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fizazi</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stopeck</LastName><ForeName>Alison T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Stony Brook Cancer Center, Stony Brook, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Janet E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Academic Unit of Clinical Oncology, Experimental Cancer Medicine Center, University of Sheffield, Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shore</LastName><ForeName>Neal D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Carolina Urologic Research Center, Myrtle Beach, South Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Montreal Hospital Centers, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Haematology, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Global Biostatistical Sciences, Amgen Inc., Thousand Oaks, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Douglas J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Clinical Development, Amgen Inc., Thousand Oaks, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>03</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27140926</ArticleId><ArticleId IdType="pii">1078-0432.CCR-15-3086</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-3086</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001511 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001511 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27140926
|texte= Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27140926" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |